Search Results 361-370 of 16727 for alopecia

1. A Study to Evaluate a Standard-dose and High- dose Regimen of Encorafenib + Binimetinib in Patients with BRAFV600-mutant Melanoma Brain Metastasis - Mayo Clinic

   Note: Stable chronic conditions (≤ Grade 2) that are not expected to resolve (such as neuropathy, myalgia, alopecia, prior therapy-related endocrinopathies) ...

2. Pediatric dermatology - Overview - Mayo Clinic

   Atopic dermatitis (eczema). Birthmarks, such as hemangioma and port-wine stain. Connective tissue disorders of the skin. Contact dermatitis. Dermatoses of ...

3. Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer - Mayo Clinic

   ... alopecia or grade 2 peripheral neuropathy prior to randomization. A washout period of at least 21 days is required between last chemotherapy dose and ...

4. A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Fruquintinib in Patients with Solid Tumors - Mayo Clinic

   Toxicity from a previous anti-tumor treatment that does not return to Grade 0 or 1 (except for alopecia). Known human immunodeficiency virus (HIV) ...

5. A Study to Evaluate the Combination of Binimetinib and Palbociclib in Treating Patients with KRAS and NRAS Mutant Metastatic or Unresectable Colorectal Cancer - Mayo Clinic

   NOTE: All toxicities from prior therapy must be ≤ Grade 1 (or ≤ Grade 2 for peripheral neuropathy or alopecia). Impaired cardiovascular function or ...

6. Clinical Study of Oral cMET Inhibitor INC280 in Adult Patients With EGFR Wild-type Advanced Non-small Cell Lung Cancer

   Patients with any grade of alopecia are allowed to enter the study. Patients must have adequate organ function; ECOG performance status (PS) of 0 or 1 ...

7. A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency - Mayo Clinic

   Adverse effect of prior therapy not resolved to CTCAE Grade 1 or below with the exception of alopecia. Ongoing Grade 2 non-hematologic toxicity related to ...

8. Head and neck cancers - Doctors and departments - Mayo Clinic

   ... Alopecia areata, Melasma, Vascular anomaly, Dermatitis, Morphea, Skin problems, Birthmarks, Vulvar skin disorder, Rosacea, Pigmentation disorder, Telogen ...

9. SL-401 in Advanced, High Risk Myeloproliferative Neoplasms (Systemic Mastocytosis, Advanced Symptomatic Hypereosinoophic Disorder, Chronic Myelomonocytic Leukemia) - Mayo Clinic

   ... alopecia, nausea, and fatigue). 2. Patient has received treatment with any disease-related therapy, including radiation therapy within 14 days of study ...

10. A Study to Compare CMP-001 Combined with Nivolumab to Nivolumab Alone in Advanced Melanoma Subjects - Mayo Clinic

    0], with the exception of persistent alopecia, adrenal insufficiency, and hypothyroidism) due to prior treatment. Active pneumonitis, history of pneumonitis ...